{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:43:29Z","timestamp":1792511009434,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010619","name":"University of Ottawa Heart Institute Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cjco.2023.11.024","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T23:32:25Z","timestamp":1701819145000},"page":"677-688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potent P2Y12 Inhibitor Selection and De-escalation Strategies in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3017-7512","authenticated-orcid":false,"given":"Laurie-Anne","family":"Boivin-Proulx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Bainey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Marquis-Gravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2023.11.024_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cjca.2017.12.012","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.11.024_bib3","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.11.024_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ahj.2006.04.012","volume":"152","author":"Wiviott","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2023.11.024_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.11.024_bib6","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2023.11.024_bib7","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2023.11.024_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.11.024_bib10","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.11.024_bib11","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.11.024_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cjco.2023.11.024_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2023.11.024_bib14","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2023.11.024_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2020.07.017","article-title":"Meta-analysis comparing the safety and efficacy of prasugrel and ticagrelor in acute coronary syndrome","volume":"132","author":"Ullah","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73871-x","article-title":"Efficacy and safety of newer P2Y(12) inhibitors for acute coronary syndrome: a network meta-analysis","volume":"10","author":"Fei","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2023.11.024_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52,816 patients from 12 randomized trials","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.11.024_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40266-021-00896-w","article-title":"Efficacy and safety of oral P2Y12 inhibitors in older patients with acute coronary syndrome: a frequentist network meta-analysis","volume":"38","author":"Shahid","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1016\/j.cjco.2023.11.024_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ehjcvp\/pvaa101","article-title":"Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials","volume":"8","author":"Montalto","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2023.11.024_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40256-019-00337-5","article-title":"Prasugrel vs. ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"19","author":"Khan","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjco.2023.11.024_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000520673","article-title":"Comparison of prasugrel and ticagrelor for patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"147","author":"Fong","year":"2022","journal-title":"Cardiology"},{"key":"10.1016\/j.cjco.2023.11.024_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10557-020-07056-z","article-title":"Prasugrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials","volume":"35","author":"Ray","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjco.2023.11.024_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001937","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis","volume":"9","author":"Farmakis","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.cjco.2023.11.024_bib24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjco.2023.11.024_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.amjcard.2015.04.050","article-title":"Comparison of ticagrelor versus prasugrel to prevent periprocedural myonecrosis in acute coronary syndromes","volume":"116","author":"Bonello","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1160\/TH13-05-0384","article-title":"Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study","volume":"111","author":"Laine","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cjco.2023.11.024_bib27","article-title":"One-year outcomes of prasugrel versus ticagrelor in acute myocardial infarction treated with primary angioplasty: the PRAGUE-18 study","author":"Motovska","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib28","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib29","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of oral P2Y(12) inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib30","article-title":"Platelet inhibition, endothelial function, and clinical outcome in patients presenting with ST-segment-elevation myocardial infarction randomized to ticagrelor versus prasugrel maintenance therapy: long-term follow-up of the REDUCE-MVI trial","volume":"9","author":"van der Hoeven","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2023.11.024_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40256-021-00504-7","article-title":"De-escalation from prasugrel or ticagrelor to clopidogrel in patients with acute coronary syndrome managed with percutaneous coronary intervention: an updated meta-analysis of randomized clinical trials","volume":"22","author":"Abdelazeem","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjco.2023.11.024_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacc.2021.06.012","article-title":"De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes","volume":"78","author":"Shoji","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ehjcvp\/pvaa025","article-title":"De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies","volume":"7","author":"Khan","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2023.11.024_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1074248418809098","article-title":"De-escalation of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials","volume":"24","author":"Kheiri","year":"2018","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cjco.2023.11.024_bib35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/1060028019845334","article-title":"Switching to clopidogrel in patients with acute coronary syndrome managed with percutaneous coronary intervention initially treated with prasugrel or ticagrelor: systematic review and meta-analysis","volume":"53","author":"Hong","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjco.2023.11.024_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/09537104.2019.1574969","article-title":"De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"31","author":"Guo","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.cjco.2023.11.024_bib37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/FJC.0000000000001252","article-title":"De-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: an updated meta-analysis and trial sequential analysis of 21 studies and 38,741 patients","volume":"79","author":"Hu","year":"2022","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjco.2023.11.024_bib38","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.11.024_bib39","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2023.11.024_bib40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.120.051700","article-title":"Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCE-POLYTECH-ACS trial","volume":"143","author":"Kim","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2023.11.024_bib41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/heartjnl-2020-318694","article-title":"Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention","volume":"107","author":"Venetsanos","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.cjco.2023.11.024_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ahj.2022.05.017","article-title":"Rationale and design of Switch Swedeheart: a registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome","volume":"251","author":"Omerovic","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2023.11.024_bib43","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"Antman","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2023.11.024_bib44","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the platelet inhibition and patient outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2023.11.024_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2004","article-title":"Ischemic and bleeding events among patients with acute coronary syndrome associated with low-dose prasugrel vs standard-dose clopidogrel treatment","volume":"3","author":"Shoji","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X23003451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X23003451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:59:28Z","timestamp":1716364768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X23003451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2589790X23003451"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2023.11.024","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent P2Y12 Inhibitor Selection and De-escalation Strategies in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2023.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}